Source: European Parliament
1. The meeting mentioned by the Honourable Member, between the Commissioner for Health and Animal Welfare and representatives of the pharmaceutical industry, was prepared in coordination with the Directorate-General for Health and Food Safety (DG SANTE), as is standard for all stakeholder engagements related to DG SANTE files. The minutes of this meeting[1] with the list of topics discussed were made public according to the Commission’s rules on transparency.
2. As regards the discussion of United States’ pharmaceutical investments, in line with the Commission’s commitment to transparency, the minutes of the meeting were published in the Transparency Register[2]. The topics discussed are listed there and focused on the pharmaceutical reform and the EU regulatory environment for medicines.
3. The Commission has not changed its position on the reform of the EU pharmaceutical legislation as set out in its proposals for revision[3] and continues to engage constructively in the ongoing negotiations with the European Parliament and the Council. Its position remains guided by the objectives of the proposal and a solid evidence base.